Proximal tubular dysfunction in a HIV-1 patient with coadministered tenofovir disoproxil-fumarate and ibuprofen
Duim, A.R.; Rokx, C.; van Gorp, E.C.M.; Rijnders, B.J.A.
Aids 29(6): 746-748
2015
ISSN/ISBN: 1473-5571
PMID: 25849839
DOI: 10.1097/qad.0000000000000575
Accession: 058655789
PDF emailed within 0-6 h: $19.90
Related References
Quinn, K.J.; Emerson, C.R.; Dinsmore, W.W.; Donnelly, C.M. 2010: Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate International Journal of Std and Aids 21(2): 150-151Mugwanya, K.; Baeten, J.; Celum, C.; Donnell, D.; Nickolas, T.; Mugo, N.; Branch, A.; Tappero, J.; Kiarie, J.; Ronald, A.; Yin, M.; Wyatt, C.; Celum, C.; Baeten, J.M.; Donnell, D.; Coombs, R.W.; Frenkel, L.; Hendrix, C.W.; Lingappa, J.R.; McElrath, M.J.; Kenya, E.; Fife, K.H.; Were, E.; Tumwesigye, E.; Ndase, P.; Katabira, E.; Ronald, A.; Bukusi, E.; Cohen, C.R.; Wangisi, J.; Campbell, J.D.; Tappero, J.W.; Kiarie, J.; Farquhar, C.; John-Stewart, G.; Mugo, N.R.; Campbell, J.D.; Tappero, J.W.; Wangisi, J. 2016: Low Risk of Proximal Tubular Dysfunction Associated with Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women Journal of Infectious Diseases 214(7): 1050-1057
Nishijima, T.; Kurosawa, T.; Tanaka, N.; Kawasaki, Y.; Kikuchi, Y.; Oka, S.; Gatanaga, H. 2016: Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy Aids 30(10): 1563-1571
Fong, T.-L.; Lee, B.T.; Tien, A.; Chang, M.; Lim, C.; Ahn, A.; Bae, H.S. 2019: Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide Journal of Viral Hepatitis 26(5): 561-567
Fong, T.-L.; Lee, B.T.; Tien, A.; Le, J.; Ahn, A.; Kim, C.; Chang, M.; Bae, H. 2018: Sa1499 - Improvement of Bone Mineral Density and Markers of Proximal Renal Tubular Function in 12 Weeks in Chronic Hepatitis B Patients Switched from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Gastroenterology 154(6): S-1133-S-1134
Van Welzen, B.J.; Thielen, M.A.J.; Mudrikova, T.; Arends, J.E.; Hoepelman, A.I.M. 2019: Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss? Aids 33(9): 1531-1534
Lockman, S.; Brummel, S.S.; Ziemba, L.; Stranix-Chibanda, L.; McCarthy, K.; Coletti, A.; Jean-Philippe, P.; Johnston, B.; Krotje, C.; Fairlie, L.; Hoffman, R.M.; Sax, P.E.; Moyo, S.; Chakhtoura, N.; Stringer, J.S.; Masheto, G.; Korutaro, V.; Cassim, H.; Mmbaga, B.T.; João, E.; Hanley, S.; Purdue, L.; Holmes, L.B.; Momper, J.D.; Shapiro, R.L.; Thoofer, N.K.; Rooney, J.F.; Frenkel, L.M.; Amico, K.R.; Chinula, L.; Currier, J.; Best, B.M.; Blanchette, C.; Browning, R.; Cheng, Y.; Fox, A.; Jaliaah, N.; Knowles, K.; Mirochnick, M.; Murtaugh, W.A.; Patras, E.; Pinilla, M.; van Wyk, J.; Whalen, F. 2021: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial Lancet 397(10281): 1276-1292
Danjuma, M.I.; Egan, D.; Abubeker, I.Y.; Post, F.; Khoo, S. 2018: Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters International Journal of Std and Aids 2018: 956462418786562
Samuels, R.; Bayerri, C.R.; Sayer, J.A.; Price, D.A.; Payne, B.A.I. 2017: Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury Aids 31(9): 1297-1301
Jotwani, V.; Scherzer, R.; Glidden, D.V.; Mehrotra, M.; Defechereux, P.; Liu, A.; Gandhi, M.; Bennett, M.; Coca, S.G.; Parikh, C.R.; Grant, R.M.; Shlipak, M.G. 2018: Pre-exposure Prophylaxis with Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals Journal of Acquired Immune Deficiency Syndromes 78(2): 169-174
Venter, W.D.F.; Sokhela, S.; Simmons, B.; Moorhouse, M.; Fairlie, L.; Mashabane, N.; Serenata, C.; Akpomiemie, G.; Masenya, M.; Qavi, A.; Chandiwana, N.; McCann, K.; Norris, S.; Chersich, M.; Maartens, G.; Lalla-Edward, S.; Vos, A.; Clayden, P.; Abrams, E.; Arulappan, N.; Hill, A. 2020: Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial LANCET. HIV 7(10): E666-E676
Wilkins, E.L.; Cohen, C.J.; Trottier, B.; Esser, S.; Smith, D.E.; Haas, B.; Brinson, C.; Garner, W.; Chuck, S.; Thorpe, D.; De-Oertel, S. 2016: Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment Aids Care 28(3): 401-408
Phuphuakrat, A.; Pasomsub, E.; Chantratita, W.; Mahasirimongkol, S.; Disthabanchong, S.; Sungkanuparph, S.; Kiertiburanakul, S. 2022: Risk Factors of Renal Tubular Dysfunction in Thai people Living with HIV Receiving Tenofovir Disoproxil Fumarate Journal of the International Association of Providers of Aids Care 21: 23259582221134751
Cui, G.; Xu, X.; Diao, H. 2015: Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B Scientific Reports 5: 11854
Mashingaidze-Mano, R.; Bwakura-Dangarembizi, M.F.; Maponga, C.C.; Morse, G.D.; Monera-Penduka, T.G.; Mtisi, T.J.; Mudzviti, T.; Mujuru, H.A. 2020: Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe Plos one 15(7): E0235759
Fung, S.; Kwan, P.; Fabri, M.; Horban, A.; Pelemis, M.; Hann, H.-W.; Gurel, S.; Caruntu, F.A.; Flaherty, J.F.; Massetto, B.; Dinh, P.; Corsa, A.; Subramanian, G.M.; McHutchison, J.G.; Husa, P.; Gane, E. 2014: Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 146(4): 980-988
Mothobi, N.Z.; Masters, J.; Marriott, D.J. 2018: Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient Therapeutic Advances in Infectious Disease 5(5): 91-95
Karris, M.Young. 2017: Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient Aids Research and Human Retroviruses 33(7): 718-722
Orkin, C.; Squires, K.E.; Molina, J.-M.; Sax, P.E.; Wong, W.-W.; Sussmann, O.; Kaplan, R.; Lupinacci, L.; Rodgers, A.; Xu, X.; Lin, G.; Kumar, S.; Sklar, P.; Nguyen, B.-Y.; Hanna, G.J.; Hwang, C.; Martin, E.A. 2019: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults with Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 68(4): 535-544
Bukkems, V.E.; Smolders, E.J.; Jourdain, G.; Burger, D.M.; Colbers, A.P.; Cressey, T.R. 2021: Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women with HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women with HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy Journal of Clinical Pharmacology 61(3): 388-393